Companies › BioLineRx
1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Sep 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Motixafortide (BL-8040) C-X-C chemokine receptor type 4 antagonist | CXCR4 | Phase 3 | Multiple Myeloma | Sep 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03246529 | Motixafortide (BL-8040) | Phase 3 | Multiple Myeloma | Oncology | Sep 2029 |
Cash and short-term investments of $21m on 2025-12-31; operating cash outflow about $8m a year; runway about 31 months at that burn, to Jul 2028; 0 of 1 coming phase 2-3 readouts fall inside that runway
Celcuity Black Diamond Therapeutics Kyntra Bio Verity Pharmaceuticals SecuraBio
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.